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Vaccinia virus (VACV) enters cells by a low pH endosomal route or by direct fusion with the plasma
membrane. We previously found differences in entry properties of several VACV strains: entry of WR
was enhanced by low pH, reduced by baﬁlomycin A1 and relatively unaffected by heparin, whereas
entry of IHD-J, Copenhagen and Elstree were oppositely affected. Since binding and entry modes may
have been selected by speciﬁc conditions of in vitro propagation, we now examined the properties of
three distinct, recently isolated cowpox viruses and a monkeypox virus as well as additional VACV and
cowpox virus strains. The recent isolates were more similar to WR than to other VACV strains,
underscoring the biological importance of endosomal entry by orthopoxviruses. Sequence comparisons,
gene deletions and gene swapping experiments indicated that viral determinants, other than or in
addition to the A26 and A25 ‘‘fusion-suppressor’’ proteins, impact entry properties.
Published by Elsevier Inc.Introduction
Entry of enveloped viruses into cells involves virion attachment,
merging of the viral and cellular membranes and release of the
core or nucleocapsid into the cytoplasm (White et al., 2008). Our
understanding of the mechanisms used by poxviruses to enter cells
has come primarily from investigations with vaccinia virus (VACV),
the prototype of the Orthopoxvirus (OPXV) genus of the Poxviridae
(Moss, 2006, 2007; Schmidt et al., 2012). The basic infectious
particle is the mature virion (MV), which consists of a nucleopro-
tein core surrounded by a lipoprotein membrane (Condit et al.,
2006). MVs can enter cells by fusing with the plasma or endosomal
membrane representing neutral and low pH pathways, respec-
tively (Armstrong et al., 1973; Carter et al., 2005; Townsley et al.,
2006). Endocytosis may occur by macropinocytosis or dynamin-
mediated ﬂuid phase uptake consistent with a role for actin
dynamics and cell signaling (Huang et al., 2008; Mercer and
Helenius, 2008; Mercer et al., 2010a; Moser et al., 2010; Moss,
2006; Sandgren et al., 2010; Villa et al., 2010). A second infectious
form of VACV known as the extracellular enveloped virus (EV)
departs the cell by exocytosis and contains an additional mem-
brane that is ultimately ruptured prior to or during the next round
of infection to allow fusion of the enclosed MV with the plasma
membrane or endocytic vesicle (Ichihashi, 1996; Law et al., 2006;
Sandgren et al., 2010; Schmidt et al., 2011).Inc.
ail.com (B. Moss).
Seneca Meadows Parkway,Four VACV proteins (A26, A27, D8 and H3) are involved in
attachment of MVs via interactions with cell surface glycosamino-
glycans (GAGs) or laminin (Chiu et al., 2007; Chung et al., 1998;
Hsiao et al., 1998; Lin et al., 2000). Twelve highly conserved, non-
glycosylated transmembrane proteins participate in subsequent
steps leading to entry of the core into the cytoplasm (Bisht et al.,
2008; Brown et al., 2006; Izmailyan et al., 2006; Nichols et al., 2008;
Ojeda et al., 2006a,b; Satheshkumar and Moss, 2009; Senkevich and
Moss, 2005; Senkevich et al., 2005, 2004; Townsley et al., 2005a,b;
Wolfe et al., 2012). Nine of the 12 proteins (A16, A21, A28, G3, G9,
H2, J5, L5, and O3) have been designated as integral components of
the entry fusion complex (EFC), two (L1 and F9) as EFC-associated,
and one (I2) has not been assessed in this regard. The phenotypes of
the EFC and EFC-associated proteins are similar except for their role
in the stability of the complex, which may depend on their location
and subunit interactions. Both EFC and EFC-associated proteins
are required for the initial fusion of viral and cellular membranes
(Laliberte et al., 2011). Absence of the I2 protein results in a
diminution of other EFC proteins in the MV raising the possibility
that it has an additional role or an indirect effect on entry (Nichols
et al., 2008).
Despite the high conservation of the membrane fusion apparatus
among poxviruses, differences in the mode of entry exist between
VACV strains (Bengali et al., 2009; Chang et al., 2010; Mercer et al.,
2010a). Notable are the different degrees of low pH enhancement
and inhibition by baﬁlomycin A1 and heparin suggesting strain-
speciﬁc preferences in attachment to cells and the use of neutral and
low pH pathways (Bengali et al., 2009). Chang et al. (2010) reported
that differences in the mode of entry of VACV strains are related to
the expression of the A25 and A26 proteins, which they refer to as
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proteins resulted in baﬁlomycin-insensitivity and enhanced fusion
of MVs with the plasma membrane of HeLa cells at neutral pH. A26
apparently suppresses fusion at neutral pH by binding to the A16
and G9 EFC proteins (Chang et al., 2012).
We suspected that VACV strains might have adapted to
particular entry pathways during their extensive passage in
cultured cells. Therefore, we were interested in examining other
OPXVs particularly those that were recently isolated from nature
including strains of cowpox virus (CPXV) and monkeypox virus
(MPXV). We found that the entry characteristic of these recent
isolates were more similar to the Western Reserve (WR) strain of
VACV, which preferentially uses a low pH-dependent endocytic
pathway, than to other VACV strains that do not. In addition,
baﬁlomycin-insensitivity of some VACV strains could not be
attributed to differences in their A26 protein, suggesting that
other factors are involved.Fig. 1. Effects of neutralizing MAb, heparin and chondroitin sulfate on entry of
recombinant LUC-expressing MVs. Puriﬁed MVs were incubated on ice with (A) 0,
5 or 20 mg/ml of MAb 7D11 for 30 min or (B and C) 0 or 50 mg/ml of heparin (HP)
or chondroitin sulfate (CS) for 30 min. The treated MVs were adsorbed to BS-C-1
cells at 4 1C for 1 h in the presence of inhibitors and then incubated at 37 1C for
1 h. Cells were lysed and LUC activity determined. (C) MPXV experiments were
conducted as described in the above panels except in a BSL-3 laboratory.
Abbreviation: RLU, relative light units.Results
Construction of OPXV recombinants that express ﬁreﬂy luciferase
(LUC)
In a previous study (Bengali et al., 2009), we compared the entry
of the following strains of VACV: WR, IHD-J, Copenhagen, New York
City Board of Health (Dryvax, Wyeth), and Elstree (Lister). The WR
strain differed from the others with regard to a several-fold enhance-
ment of entry by brief low pH treatment prior to or after virus
attachment to cells. WR also differed from IHD-J, Copenhagen and
Lister with respect to greater inhibition of entry by baﬁlomycin A1
and lower inhibition of attachment by heparin. For the present study,
we selected an additional VACV strain, Modiﬁed VACV Ankara
(MVA), because of its deployment as a safe smallpox vaccine and
as a vector for a variety of infectious diseases and the Brighton strain
of CPXV (CPXV-BR) because of its use for evaluation of poxvirus
therapeutics and pathogenesis studies. We were particularly inter-
ested, however, in three CPXV strains with distinct genome sequence
differences isolated in Germany from humans (GER_1990_2 and
GER_1991_3) and a monkey (GER_2002_MKY) (Carroll et al., 2011;
Meyer et al., 1999), and the MPXV strain ZAI-1979-005 isolated from
a fatal human infection (Breman et al., 1980) because of their better
provenance and fewer in vitro passages compared to VACV strains.
VACV WR and VACV IHD-J were used for comparison as they
represented prototypes of the two entry modes found in our
previous VACV studies.
Poxviruses package a complete system for transcription of early
genes, which occurs almost immediately following entry of cores into
the cytoplasm. Based on this attribute, we previously constructed
recombinant VACVs that express ﬁreﬂy LUC at early times and
analyzed enzyme activity as a sensitive and quantitative measure of
virus entry (Bengali et al., 2009; Townsley et al., 2006). We inserted
the same LUC expression cassette into the homologous F12-F13
intergenic regions of other VACVs as well as the CPXV strains and
MPXV in order to analyze their entry into cells. Neutralization of each
of the OPXVs with the monoclonal antibody (MAb) 7D11 to the
conserved VACV L1 entry protein prevented LUC expression, demon-
strating the speciﬁcity of the assay (Fig. 1A). L1 MAb inhibits at a
post-hemifusion step prior to entry of the core into the cytoplasm
(Laliberte et al., 2011).
Effects of soluble GAGs on entry of OPXVs
Heparin was previously shown to exert a differential effect on
the entry of VACV strains. At a concentration of 50 mg/ml, entry of
VACV WR was inhibited by approximately 20% whereas VACVIHD-J was inhibited by 90% (Bengali et al., 2009). Further analysis
indicated that heparin prevented the binding of IHD-J to cells. We
found that MVA was as sensitive to heparin as the IHD-J strain; in
comparison, the other OPXVs were much less sensitive to heparin
than IHD-J and in this regard were similar to WR (Fig. 1B and C).
Chondroitin sulfate had a much less inhibitory effect than heparin
on MVA and IHD-J and did not show a strong strain-speciﬁc effect
(Fig. 1B and C).
Effects of low pH and inhibition of endosomal acidiﬁcation
VACV WR is stimulated several fold by brief low pH treatment
immediately following adsorption and inhibited by 50% or more
by baﬁlomycin A1, whereas IHD-J is relatively unaffected by low
pH or baﬁlomycin A1 (Bengali et al., 2009). MVA was also
unaffected by the low pH pulse (Fig. 2A), resembling IHD-J. Three
of the recent CPXV strains exhibited a modest stimulation of
1.5- to 2.5-fold and one (GER_1990_2) was stimulated more than
4-fold, similar to VACV WR (Fig. 2A).
VACV IHD-J and MVA were relatively insensitive to baﬁlomycin
A1, while VACV WR, the three recent isolates of CPXV and MPXV
were strongly inhibited (Fig. 2B and C). CPXV-BR exhibited inter-
mediate sensitivity to baﬁlomycin A1 (Fig. 2B).
Effects of actin and cell-signaling inhibitors
Mercer et al. (2010a) compared the effects of a number of
inhibitors on entry of WR and IHD-J strains of VACV. We extended
Fig. 2. Effects of low pH and baﬁlomycin A1 treatment on cell entry of LUC-expressing recombinant MVs. (A) BS-C-1 cells were incubated with MVs at a multiplicity of
1 plaque forming unit (PFU) per cell at 4 1C for 1 h, followed by washing to remove unbound virus and exposure to pH 5 or pH 7.4 buffer for 3 min at 37oC. Cells were then
washed and incubated at 37 1C at neutral pH for 1 h. Cells were lysed and LUC activity measured. The ratios of LUC activity following low and neutral pH are plotted for
each virus. Error bars are shown. (B and C) BS-C-1 cells were pretreated with 0, 10 or 40 nM baﬁlomycin A1 for 1 h at 37 1C. Pretreated cells were incubated with indicated
recombinant MVs in the presence of baﬁlomycin A1 for 1 h at 4 1C, unattached virus was removed by washing, and the cells were incubated at 37 1C at for 1 h in the
absence or presence of baﬁlomycin A1. The cells were lysed and LUC activity measured. Abbreviation: RLU, relative light units.
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cytochalasin D and latrunculin, the protein kinase inhibitor
genestein, and the phosphoinositide 3-kinase inhibitor wortmannin
on three strains of VACV and four strains of CPXV. Inhibitors were
tested at two concentrations in order to better evaluate sensitivities.
Cytochalasin D inhibited entry of all of the OPXVs, although VACV
IHD-J and MVA appeared less sensitive than others (Fig. 3A).
Similarly, IHD-J and MVA appeared less sensitive to latrunculin A,
another actin inhibitor (Fig. 3B). Entry of each of the OPXVs was
strongly inhibited by genestein (Fig. 3C). IHD-J and MVA were the
least sensitive to wortmannin. With respect to WR and IHD-J, our
data with cytochalasin D and wortmannin agreed with Mercer et al.
(2010a); however IHD-J and WR appeared similarly sensitive to
genestein in our hands. Overall, IHD-J and MVAwere most similar to
each other and VACVWR grouped with the other OPXVs that appear
to prefer the endosomal route (Table 1).
Effect of deletion and swapping of the A26 ORF on baﬁlomycin A1
sensitivity
Chang et al. (2010) reported that baﬁlomycin A1-insensitivity of
VACV correlated with loss of either the A26R or A25R gene, which
act as fusion suppressors. The A26 open reading frame (ORF)
sequences of six VACV strains, MPXV, CPXV-BR and the three
recent CPXV isolates are shown in Fig. S1 and summarized in
Table 1. MVA and Copenhagen have truncated A26 ORFs. However,
the A26 ORFs of the other VACV strains were 500 to 502 amino
acids long and 99% identical to that of WR. Except for CPXV-BR, the
CPXV and MPXV A26 ORFs were longer than those of VACV mainly
due to a longer run of aspartates in the CPXV isolates and had490% identity with WR. The CPXV strains all had conserved full-
length A-type inclusion protein sequences and made large ATI
bodies; except for CPXV-BR the ATIs contained occluded MVAs
(personal communication of R. Kastenmeyer and A. Weisberg).
Neither MPXV nor the VACV strains make ATIs as the correspond-
ing ORF is truncated at the C-terminus to form the A25 protein or
largely missing in the case of MVA and Copenhagen. Although the
baﬁlomycin A1 insensitivity of MVA and Copenhagen strains of
VACV could be related to truncations of the A26 ORFs, the
insensitivity of IHD-J and Elstree could not (Table 1). Furthermore,
like WR, the A26 and A25 proteins of IHD-J and Elstree were
synthesized and incorporated into MVs as shown by Western
blotting with polyclonal antibodies that recognized the homolo-
gous proteins of the three VACV species (Fig. 4A and B). To further
investigate the relationship between A26 and the low pH entry
mode, we constructed WR and IHD-J deletion mutants and also
swapped A26 ORFs of the two VACV prototype strains. A27, which
binds A26, was not swapped because the ORFs of these two strains
are identical. Western blots showed the presence of the swapped
A26 proteins in the MVs of the WR and IHD-J recombinant viruses
and the absence of the A26 protein in the deletion mutants
(Fig. 4A). Although the A25 and A26 proteins interact with each
other (Howard et al., 2008), A25 still associates with MVs in the
absence of A26 indicating an interaction with an additional protein.
Next, we measured entry of the wild type and mutant MVs
using the LUC assay. Deletion of the A26 ORF from WR or IHD-J
did not enhance baﬁlomycin A1 inhibition of MV entry in either
BSC-1 (Fig. 5A) or HeLa (Fig. 5B) cells. Furthermore, the swapping
of WR and IHD-J A26 ORFs did not alter the baﬁlomycin A1
sensitivity of the recipient virus (Fig. 5A and B).
Fig. 3. Effects of cytochalasin D, latrunculin A, genestein and wortmannin on entry of LUC-expressing recombinant MVs. BS-C-1 cells were pretreated with (A) 0, 0.5 or
2.0 mg/ml of cytochalasin D; (B) 0, 0.5 or 2 mM latrunculin; (C) 0, 20 or 100 mM genestein; (D) 0, 0.5 or 1.0 mM wortmannin. Cells were infected and incubated as in Fig. 2
and LUC activity determined. The percent activity relative to 0 drug was plotted with error bars.
Table 1
Properties of Orthopoxviruses.
Number of plus marks indicates relative enhancement of entry with low pH or
decrease in entry by inhibitors. Shaded rows refer to experimental data obtained
previously (Bengali et al., 2009). nd, not done
abaﬁlomycin A1.
bheparin.
ccytochalasin A and latrunculin.
dgenestein.
ewortmanin.
f(length in amino acids/% identity to WR).
gACAM3000.
hACAM2000.
Fig. 4. Detection of A26 and A25 in puriﬁed recombinant MVs. (A) Puriﬁed Luc-
recombinant MVs of VACV strains WR and IHD-J, A26 deletion mutants VACV
WR(DA26) and VACV IHD-J(DA26), and swap mutants VACV WR(IHD-J A26) and
VACV IHD-J(WR A26) were analyzed by Western blotting with antibody to the
VACV A26 protein and the CPXV ATI protein, which recognizes VACV A25 because
of high sequence conservation. (B) VACV WR, VACV WR(DA26) and VACV Elstree
MVs were analyzed as in panel A.
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The ability of exogenous VACV to induce the formation of syncytia
following adsorption has been referred to as fusion from without
(Gong et al., 1990). As originally described, high virus multiplicities
and a low pH pulse are required for cell–cell fusion. Recently, Chang
et al. (2010) reported that VACV WR A25 and A26 deletion mutants,
unlike wild type WR, could trigger syncytia formation at neutral pH.
We followed the procedure of Chang et al. (2010) by mixing HeLa
cells expressing orange ﬂuorescent protein with HeLa cells expressinggreen ﬂuorescent protein at a ratio of 1:1. The cells were either mock
infected or infected with a high multiplicity of puriﬁed MVs. After
adsorption, phosphate buffered saline at pH 7.4 or 5.0 was provided
for 2 min. The buffer was then removed and the incubation continued
with neutral pH medium for an additional 1 h. The mock-infected
monolayer was composed of individual orange and green cells at
the latter time after either pH 5.0 or pH 7.4 treatments (Fig. 6). The
WR- and IHD-J-infected monolayers that had brief pH 5.0 incubations
were almost completely fused but there were only small numbers of
fused cells in the absence of the low pH pulse (Fig. 6). The syncytia-
forming abilities of theWR and IHD-J strains with swapped A26 ORFs
were similar to their parents (not shown). In contrast, cells infected
with WR or IHD-J A26 deletion mutants showed enhanced syncytia
formation at neutral pH, which was increased further with a low pH
pulse (Fig. 6). MVA showed extensive syncytia formation after either
pH treatment (not shown).
Fig. 5. Effect of baﬁlomycin A1 on entry of LUC-expressing mutant viruses. BS-C-1
(A) and HeLa (B) cells were treated with baﬁlomycin A1, infected with LUC-
expressing WR and IHD-J or A26 deletion mutants or swap mutants deﬁned in the
legend to Fig. 4. LUC activity was measured as described in the legend to Fig. 2.
Fig. 6. Fusion from without. HeLa cells were separately transfected with plasmid
expressing CMV-promoter controlled orange ﬂuorescent protein or green ﬂuor-
escent protein. After 24 h, the cells were harvested, mixed in 1:1 ratio and plated
together in a 96-well plate. After forming a monolayer, the cells were infected
with 100 PFU of puriﬁed virus per cell, treated with either pH 7.4 or 5.0 buffer for
2 min, and incubated in neutral pH medium for additional 1 h at 37 1C. Fluorescent
cells were detected with a Leica DM IRB ﬂuorescent microscope.
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We previously reported that VACV strains varied in their entry
pathways as determined by low pH enhancement and inhibition
by baﬁlomycin A1 and heparin (Bengali et al., 2009). Indeed, the
low pH enhancement and baﬁlomycin A1 sensitivity of the WR
strain appeared exceptional compared to several other VACV
strains tested. However, the origin of VACV is unknown and most
strains have been extensively propagated in cell culture. It
seemed possible, therefore, that strain differences were selected
by particular virus growth conditions. To extend these studies, we
analyzed recently isolated OPXVs. There is evidence that CPXV is
comprised of several diverse species (Carroll et al., 2011). We
obtained three genetically distinct CPXVs isolated from documen-
ted human and monkey infections as well as a highly pathogenic
MPXV isolate. The entry properties, determined using a LUC
expression assay, are summarized in Table 1. The three recent
CPXV isolates were similar to each other and to VACV WR with
regard to sensitivity to baﬁlomycin A1, cytochalasin, latrunculin,
genestein, and wortmannin and by their resistance to heparin.
The degree of enhancement by low pH, however, varied. The
latter result was not too surprising as low pH stimulation appears
to be due to at least two factors of which one can be separated
from baﬁlomycin A1 sensitivity (Townsley and Moss, 2007).
Although analyzed less extensively, MPXV seemed similar to the
CPXVs. Our ﬁnding that the WR strain of VACV resembled the
recent CPXV isolates was gratifying, as WR is the prototype OPXV
for laboratory studies. Based on the baﬁlomycin A1-sensitivity,
we concluded that the low pH endocytic pathway is a major route
of entry by OPXVs and that preferential neutral pH entry pathway
of some VACV strains was likely acquired during laboratory
passage. In support of this idea, IHD_J enters HeLa cells more
rapidly than WR (Bengali et al., 2009). In cells with a dense
cortical layer, however, endocytosis may have an advantage over
fusion at the plasma membrane (Mercer et al., 2010b). In addition,the previously noted inverse relationship between baﬁlomycin
A1 and heparin sensitivity (Bengali et al., 2009) held up with the
additional viruses studied here. This feature suggests that adaptation
to entry through the plasma membrane relies on binding to GAGs.
While the present work was proceeding, Chang and coworkers
reported that the A25 and A26 proteins served as fusion suppres-
sors and that fusion with the plasma membrane and baﬁlomycin
A1-resistance were enhanced in the absence of either (Chang
et al., 2010). They further reported that the absence of A26
correlated with VACV strain speciﬁcity (although their IHD-J
strain and ours appear to differ in baﬁlomycin sensitivity) and
that A26 interacts with components of the EFC (Chang et al.,
2012). The A25 protein is a truncated form of the A-type inclusion
protein of CPXV but is conserved in many OPXVs that do not form
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MVs within A-type inclusions of CPXV (McKelvey et al., 2002) and
contributes to cell attachment by binding to laminin (Chiu et al.,
2007). A26 is complexed with both A25 and A27 and is tethered
via the latter to the A17 transmembrane protein on the MV (Ching
et al., 2009; Howard et al., 2008). A25 presumably interacts
directly with either A27 or A17 since it still associates with MVs
lacking A26. Neither A25 nor A26 is a component of EVs (Ulaeto
et al., 1996) and may be missing from a small subset of MVs that
are precursors to EVs.
We had not originally considered a speciﬁc role for A25 or A26
with regard OPXV entry pathways because we knew that both of
these ORFs are highly conserved in the baﬁlomycin A1 insensitive
IHD-J and Elstree strains and the baﬁlomycin A1 sensitive WR and
Wyeth strains. Moreover, neither full-length nor truncated ATI
protein is present in puriﬁed CPXV MVs (Patel et al., 1986).
Nevertheless, upon learning of the data from the Chang laboratory
(Chang et al., 2010), we compared the A26 sequences and the A25
or ATI protein sequences of all of the OPXVs used in our present
and previous study. The recently isolated CPXVs all had conserved
A26 ORFs and full-length ATI proteins, whereas CPXV-BR has a
truncated A26 and full-length ATI. Since CPXV-BR is less sensitive
to baﬁlomycin A1 than the more recent CPXV strains, this
difference would be consistent with a role for A26 in regulating
the entry pathway. As Chang et al. (2010) previously noted, the
MVA and Copenhagen strains of VACV have truncated A26
proteins and are missing A25 and we also ﬁnd that they are
baﬁlomycin A1 insensitive. However, this leaves us with the
conundrum as to why the IHD-J and Elstree strains were baﬁlo-
mycin A1 resistant, though they have conserved A26 and A25
ORFs. One possibility was that the A26 and A25 proteins were not
expressed or expressed but not present in MVs. However, we
showed that puriﬁed IHD-J and Elstree MVs, like WR MVs, have
both proteins. Moreover, deleting A26 from WR and IHD-J did not
alter their relative sensitivities to baﬁlomycin A1, nor did swap-
ping the A26 ORFs. We did ﬁnd, however, that deleting the A26
ORFs from WR and IHD-J enhanced their ability to induce HeLa
cells to undergo fusion from without at neutral pH. While
syncytium formation is related to entry and requires the entry-
fusion complex, there are obvious differences including the very
high virus multiplicity (100 PFU per cell or more) used for the
latter, whereas our entry studies were carried out at a multiplicity
of 1 PFU per cell.
There are some experimental differences between our studies
and those of Chang et al. The majority of our entry experiments
were carried out with BS-C-1 cells, whereas the Chang laboratory
used mainly HeLa cells. They reported (Chang et al., 2010) that
WR A25 and A26 deletion mutants remained sensitive to baﬁlo-
mycin A1 in BS-C-40 (derived from BS-C-1) cells and human
umbilical vein cells in contrast to HeLa, L and CHO cells. Thus,
data from our laboratory as well as the Chang laboratory are
consistent with additional viral and cell factors controlling OPXV
entry pathways.Materials and methods
Cells and viruses
African green monkey kidney BS-C-1 and human HeLa S3 cells
were maintained in minimum essential medium with Earle’s salts
(EMEM, Quality Biological, Gaithersburg, MD). The medium was
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
100 units/ml penicillin, and 100 mg/ml streptomycin. The following
strains of VACV were used: WR (ATCC VR-1354; GenBank accession
number NC_006998), IHD-J from S. Dales, and MVA (ATCC VR-1508).CPXV-Br was obtained from ATCC (VR-302) and CPXV GER_1990_2,
CPXV GER_1991_3 and CPXV GER_2002_MKY from H. Meyer (Carroll
et al., 2011; Meyer et al., 1999). MPXV-ZAI-1979-005 was provided
by I. Damon. Recombinant WRvFire and IHD-JvFire expressing ﬁreﬂy
LUC via a synthetic early-late promoter were previously described
(Bengali et al., 2009; Townsley et al., 2006). Similar vFire recombi-
nants were made using the CPXV and MPXV strains. MVs were
puriﬁed by sedimentation through two 36% (w/v) sucrose cushions
and banding once on a 25–40% (w/v) sucrose gradient for all
experiments. Puriﬁed stocks were stored at 80 1C and sonicated
on ice for 1 min prior to infection. Studies with VACV and CPXV
strains were carried out under BSL-2 conditions. MPXV studies were
carried out in a BSL-3 laboratory with approval by NIH and the
Centers for Disease Control and Prevention.
Luc entry assay
The assay was carried out essentially as described (Townsley
et al., 2006). Virus was allowed to adsorb for 1 h at 4 1C at neutral
pH. Unattached virus was removed by washing. For pH activation,
the cells were incubated for 3 min at 37 1C with Dulbecco’s
phosphate buffered saline with Ca2þ and Mg2þ at pH 7.4 or
adjusted with HCl and 1 mM 2-morpholinoethane-sulfonice acid
to pH 5. The pH was then neutralized and washed with EMEM
containing 2.5% FBS, 2 mM L-glutamine, 100 units/ml penicillin, and
100 mg/ml streptomycin (EMEM-2.5) and incubated with 1 ml
EMEM-2.5 at 37 1C for 1 h. Cells were then harvested by washing
with phosphate buffered saline (pH 7.4) and incubation with 300 ml
of Cell Culture Lysis Reagent (Promega, Madison, WI) for 30 min at
room temperature on an orbital shaker. Luc assay was performed by
adding 20 ml of cell lysate to 100 ml of luc activity assay substrate
(Promega), mixed, and chemiluminescence was measured using a
luminometer (Berthold Sirius, Bad Wilbad, Germany).
Inhibition of endosomal acidiﬁcation
Cells were treated with baﬁlomycin A1 (Sigma, St. Louis, MO) at
10 or 40 nm for 1 h at 37 1C, which remained present throughout
the adsorption and subsequent incubations.
Effects of other inhibitors on virus entry
Virus was treated with heparin (50 mg/ml) and chondroitin
sulfate (50 mg/ml) (Sigma) in EMEM-2.5 for 30 min on ice. Without
removing the inhibitors, virus was added to cells for adsorption at
neutral pH as described above. Additional drugs were obtained
from Sigma and stock solution made in DMSO. Drug was diluted in
tissue culture media at the indicated concentrations and incubated
with cells for 1 h at 37 1C and remained present throughout the
adsorption and subsequent incubations.
Fusion from without
HeLa cells were transfected with plasmid expressing CMV-
promoter controlled orange ﬂuorescent protein or green ﬂuores-
cent protein. At 24 h post-transfection, cells were harvested by
trypsinization, mixed in 1:1 ratio and plated together in a 96-well
plate. After forming a monolayer (12–16 h post-plating), the cells
were infected with 100 PFU of puriﬁed virus per cell for 1 h at
4 1C. Cells were washed to remove unbound viruses, treated with
either pH 7.4 or 5.0 buffer for 2 min, washed and incubated in
neutral pH E-MEM for additional 1 h at 37 1C. Cells were ﬁxed
with 4% paraformaldehyde for 15 min, ﬂuorescent cells were
visualized with a Leica DM IRB ﬂuorescent microscope and images
were processed by Adobe Photoshop software to determine cell–cell
fusion.
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